Patent Expiry and Adverse Effects of Erectile Dysfunction Drugs Oppose Growth of Global Market, Says TMR
The global erectile dysfunction (ED) drugs market is poised to decline in the coming years as blockbuster drugs near patent expiration. The loss of exclusivity for the leading players will translate into an entry point for various generic drugs, thus making the competition stiffer and prices remarkably lower. For instance, the Cialis (tadalafil) is anticipated to lose its patent exclusivity by 2017, while Levitra/Staxyn (vardenafil) will experience a patent cliff by 2018. On the other hand, Viagra (sildenafil citrate) will lose its exclusivity in the U.S. by October 2020. This factor is expected to tug the market in the opposite direction of growth in the coming few years.
Q. How much will the market suffer during the forecast period?
A. Transparency Market Research reported that the value of the global erectile dysfunction drugs market was worth US$4.3 bn in 2012 and is anticipated to dip to US$3.4 bn by end of 2019. The overall market is anticipated to plummet at a CAGR of 4.5% during the forecast period of 2013 and 2019. The growth of the market is also expected to be stymied by the rising risk of sexually transmitted diseases (STDs) due to the first line of treatment for erectile dysfunction. Research indicates that ED drug users have higher chances of acquiring HIV and Chlamydia infections. The poor insurance coverage for those opting for ED treatment is also hampering the growth of the global market as insurance companies view this inability of the human body as a non-essential one.
Q. What are the possible growth opportunities for the global erectile dysfunction drugs market?
A. The ever-changing dynamics of the global demand and consumer preferences offer the global erectile dysfunction drugs market few lucrative opportunities to bounce back from the projected pitfall. Companies can offset the shortcomings of drugs available in the global market through topical ointments and creams. Innovations in drug delivery techniques such as MUSE (medicated urethral system for erection) drug and Vitaros (alprostadil) by Apricus Biosciences, Inc. and Meda Pharmaceuticals, Inc. are expected to open up new perspectives towards operating businesses in the near future. Companies are anticipated to focus on combination therapies to tackle the issue of both side-effects of ED drugs and the problem of ED amongst patients.
Q. Which brand is anticipated to lead the global market?
A. The brands available in the global market are Viagra, Levitra/Staxyn, Stendra/Spedra, MUSE, Zydena, Mvix, and Helleva. Of these, Viagara, which is the brand name for sildenafil cirate, is anticipated to lead the global market. As of 2013, the drug held a share of 45% in the global erectile dysfunction market. This drug is anticipated to earn monumental revenues as it still retains a patent exclusivity till 2020 in the U.S. market. Despite its patent expiry in other regions, other pharmaceutical companies will not be able to label their products under the same brand name, which will keep the sales of Viagra up as the product has earned a sizeable brand equity over the past few decades.
The research report estimates that there are about 150 million men suffering from ED across the globe. Out of these, about 30 million are from the U.S. alone and the figure is only estimated to double by 2025. Thus, North America is projected to lead the global market in the coming years. The growth of the erectile dysfunction drugs market in North America will also be supported by the presence of a large number of leading players in the region.